Latest From Mobidiag Ltd.
Pacts In Medtech: Amarantus And Todos Form Breakthrough Diagnostics Inc.; Edwards Teams Up With Bay Labs To Find Heart Disease
Derived from Strategic Transactions, Informa's premium source for tracking life-sciences deals, the bimonthly Pacts In Medtech feature highlights notable technology alliances, R&D partnerships and commercial collaborations. This edition covers industry pacts that were sealed in November and December 2018.
Finnish molecular diagnostics company Mobidiag is partnering with Chinese company Autobio Diagnostics in a new joint venture to commercialize its Novodiag platform for infectious disease diagnostics.
Medtech companies brought in $2.3 billion in financing in Q1 2017, a slight decrease from Q4 2016; device M&A deals totaled $5.8 billion, a sharp decline from the prior quarter, but there were some billion-dollar deals. Q1 diagnostics financings – totaling $1.2 billion (thanks to a $900 million Series B round by cancer diagnostics company Grail) – showed a significant increase over the preceding quarter, as did the Q1 M&As at $700 million versus the previous $87 million.
Derived from Strategic Transactions, Informa’s premium source for tracking life-sciences deals, the bi-monthly Pacts In Medtech column pulls up notable technology alliances, R&D partnerships and commercial collaborations. This month we highlight deals announced in January and February 2017.
In Vitro Diagnostics
- Chemistry, Immunoassay
- Molecular Diagnostics & Genetic Testing
Research, Analytical Equipment & Supplies
- PCR & Amplification Tools
- Therapeutic Areas
- Infectious & Viral Diseases
- Mobidiag Oy
- Western Europe
- Parent & Subsidiaries
- Mobidiag Ltd.
- Senior Management
- Tuomas Tenkanen, CEO
- Contact Info
Phone: 10 5050 770
Keilaranta 16 A
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.